Welcome to our dedicated page for Vivos Therapeutics news (Ticker: VVOS), a resource for investors and traders seeking the latest updates and insights on Vivos Therapeutics stock.
Overview
Vivos Therapeutics Inc is a specialized medical technology company dedicated to addressing sleep disordered breathing (SDB) with a focus on mild-to-moderate obstructive sleep apnea (OSA). Leveraging industry-specific technology and customized oral appliance therapy, the company offers a non-surgical, non-invasive, and low-cost solution that distinguishes it within the competitive landscape of sleep health and medical devices. Key industry terms such as "obstructive sleep apnea", "sleep disordered breathing", and "oral appliance therapy" underscore its commitment to innovative clinical solutions.
Business Model and Operations
The company operates through two core revenue streams. One stream involves the development, commercialization, and direct distribution of customized oral appliances that integrate proprietary clinical protocols. These protocols, often administered by specially trained dentists in collaboration with other healthcare professionals, provide an alternative therapy to traditional CPAP treatments. The second stream is driven by the company’s licensing of its intellectual property, allowing third-party manufacturers to produce therapeutic devices according to the specialized Vivos System guidelines.
Clinical Protocols and Healthcare Integration
At the heart of Vivos Therapeutics is its Vivos System, a treatment protocol that combines device customization with targeted clinical methodologies. Through its integrated healthcare network, the company connects general dentists, medical doctors, myofunctional therapists, and chiropractors, creating a collaborative ecosystem focused on treating SDB. This structure not only facilitates patient access to specialized care but also supports the standardization of care practices within the field of sleep medicine.
Innovation and Industry Positioning
Vivos Therapeutics distinguishes itself by emphasizing non-surgical and non-pharmaceutical approaches to managing OSA. Its focus on low-cost, patient-centric treatment solutions aims to enhance accessibility and compliance, contributing to its competitive positioning against conventional therapies such as CPAP devices. The company’s ongoing efforts to refine its treatment methodologies and expand its integrated network underscore its commitment to clinical excellence and technological advancement.
Research and Development Focus
Innovation remains central to Vivos Therapeutics' strategy. The development of customizable treatment protocols and proprietary oral appliances represents a blend of technical expertise and clinical insight. The company’s research and development efforts not only drive its product offerings forward but also position it as a key contributor within the sleep health arena. By collaborating with clinical experts and leveraging insights from real-world healthcare practices, Vivos continually refines its approach to meet evolving patient needs.
Market and Competitive Landscape
Operating within the broader medical device industry, Vivos Therapeutics faces the dual challenge of technological advancement and regulatory compliance. Its focus on offering a tangible alternative to surgical and pharmaceutical interventions sets it apart. Competitors may include traditional CPAP providers and other oral appliance manufacturers; however, Vivos’ integrated clinical protocols and licensing model offer a unique value proposition that enhances its industry credibility. The company’s strategy to work closely with an array of healthcare providers also reinforces its role as a pivotal player in specialized sleep disorder treatment.
Conclusion
In summary, Vivos Therapeutics Inc provides a distinct approach to managing mild-to-moderate OSA through the use of custom oral appliances and an integrated treatment protocol. Its operations, characterized by dual revenue pathways and a comprehensive healthcare network, illustrate a robust business model suited for the evolving landscape of sleep medicine. This detailed look at its operations, innovation practices, and market positioning provides investors and industry observers with a clear understanding of its core competencies and strategic framework.
Vivos Therapeutics has received FDA 510(k) market clearance for its mmRNA device, a non-invasive treatment for mild to moderate obstructive sleep apnea (OSA). This approval increases the potential for insurance reimbursement, including Medicare. With over 54 million Americans affected by sleep apnea, Vivos aims to provide a cost-effective alternative to current treatments. The company also plans to appeal the FDA's denial of its DNA appliance application, although this is not expected to impact existing operations significantly.
Vivos Therapeutics (NASDAQ: VVOS) has released detailed results from a national study on its FDA Class 1 DNA appliance for sleep-disordered breathing. The data indicates that one in four patients reported complete resolution of obstructive sleep apnea (OSA) symptoms. Among 20 patients with severe OSA, average improvement in AHI scores was 53%, with none reporting worsening symptoms. The average improvement for 18 patients with moderate OSA was 64%. The results highlight the effectiveness of Vivos' treatment protocols compared to traditional methods.
Vivos Therapeutics reported a 37.5% increase in Q2 revenue, reaching $4.5 million, and a 30% rise from Q1 2021. Gross profit for Q2 was $3.6 million, with an 81% gross margin. However, the company faced a net loss of $4.0 million for the quarter, up from <$1.4 million> in Q2 2020. Vivos has treated over 19,000 patients and opened a training center in Denver. New initiatives, including the VivoScore test, have shown a significant increase in sleep apnea testing, indicating expanding market adoption.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) will present at the Q3 Virtual Investor Summit on August 18, 2021, at 9:30 am EST. The presentation will feature CEO Kirk Huntsman, CFO Brad Amman, and Investor Relations Officer Ed Loew. Vivos focuses on developing innovative treatments for sleep-disordered breathing, including obstructive sleep apnea (OSA). The company’s Vivos System offers a non-invasive, cost-effective solution using customized oral appliances, proven effective in over 19,000 patients globally. Interested investors can register for the presentation online.
Vivos Therapeutics (NASDAQ: VVOS) will release its second-quarter financial results after market close on August 12, 2021, with a conference call scheduled for 5:00 p.m. ET the same day. This call will cover the company's financial performance, recent milestones, and growth strategy. Vivos specializes in innovative treatments for sleep-disordered breathing, particularly obstructive sleep apnea. The company offers the Vivos System, a non-invasive oral appliance treatment that has benefitted over 19,000 patients worldwide through 1,250 dentists.
Vivos Therapeutics has announced the opening of The Vivos Institute in Denver, Colorado. This 15,000-square-foot training facility aims to significantly enhance education for healthcare providers on treating obstructive sleep apnea (OSA). The Institute can train 300 to 400 professionals daily, offering hands-on education about OSA and Vivos’ treatments. Key funding of over $500,000 in equipment was donated by dental and medical supply companies. The opening is part of Vivos' mission to improve awareness and treatment options for sleep-disordered breathing.
Vivos Therapeutics (NASDAQ: VVOS) announced results from a national study involving 74 adult patients with obstructive sleep apnea (OSA) treated with its FDA Class 1 DNA appliance. The study revealed that 28% of patients reported no remaining OSA symptoms post-treatment. Additionally, 82% showed improvement in their Apnea Hypopnea Index (AHI) scores, with 64% improving by at least one category. The average treatment lasted 14 months, and findings have been submitted to the FDA for 510k clearance. Vivos believes their technology may be a breakthrough for OSA treatment.
Vivos Therapeutics (NASDAQ: VVOS) announced positive results from an independent patient survey regarding its treatment for obstructive sleep apnea (OSA). Key findings show that 97% of patients achieved their desired outcomes with Vivos treatment, while 63% sought dentists' advice for solutions. The treatment typically lasts 12 to 24 months and addresses dental tissue anomalies linked to OSA, providing a non-invasive alternative to CPAP. The survey involved 123 patients and was executed by The EyeDeas Company in June 2021.
Vivos Therapeutics, Inc. (NASDAQ: VVOS) announced the release of a new book by its Founder and Chief Medical Officer, Dr. G. Dave Singh, aimed at helping medical professionals understand craniofacial conditions affecting sleep health. The book, titled Pneumopedics and Craniofacial Epigenetics, explores the link between dentofacial anomalies and obstructive sleep apnea (OSA). Vivos’ technology offers a non-invasive treatment for mild-to-moderate OSA, now proven effective in over 17,000 patients. The book serves as a culmination of Dr. Singh's research and aims to advance understanding of innovative therapy options.
Vivos Therapeutics (NASDAQ: VVOS) reported its Q1 2021 financial results, revealing a revenue of $3.4 million, an 8% increase from Q1 2020. Gross profit rose by 11% to $2.7 million with a gross margin of 78%. However, net loss increased to $3.4 million from $2.6 million year-over-year. The company bolstered its finances with a follow-on offering generating $27.6 million in May. Recent developments include the launch of AireO2 software and VivoScore home testing services, along with the opening of Pneusomnia Centers aimed at enhancing treatment options for sleep disorders.
FAQ
What is the current stock price of Vivos Therapeutics (VVOS)?
What is the market cap of Vivos Therapeutics (VVOS)?
What is the core focus of Vivos Therapeutics Inc?
How does the company generate its revenue?
What is the Vivos System?
Who are the primary beneficiaries of Vivos Therapeutics' services?
What distinguishes Vivos Therapeutics from traditional CPAP therapies?
How does Vivos Therapeutics integrate with the healthcare ecosystem?
What market challenges does Vivos Therapeutics face?
How does Vivos Therapeutics demonstrate industry expertise?
